Sign in

CIK 0001404644

  • Non-accelerated filer
  • Smaller reporting company

Neurogene Inc.

Sign in to watch
Ticker
NGNE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
980542593
Phone
+1 877-237-5020
Business address
535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
Former names
Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Planned sale Chief Scientific Officer sold 6,797 shares at $15.15 ($103,003)
  12. 4 Grant or award Chief Scientific Officer acquired 7,200 shares (grant or award)
  13. 4 Grant or award President and CFO acquired 20,300 shares (grant or award)
  14. 4 Grant or award Chief Medical Officer acquired 8,400 shares (grant or award)
  15. 4 Grant or award Chief Executive Officer acquired 23,900 shares (grant or award)
  16. 4 Planned sale President and CFO sold 4,501 shares at $16.94 ($76,247)
  17. 4 Open-market buy 10% owner bought 48,770 shares at an average $25.83 ($1,259,623)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Open-market buy President and CFO bought 24,000 shares at $20.48 ($491,400)
  20. 4 Open-market buy Chief Executive Officer bought 47,500 shares at $20.40 ($969,000)

Page 2 of 15 · 287 filings